MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Lantheus Holdings ROCE Ratio 2011-2026 | LNTH
Annual ROCE Ratio Lantheus Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.52 | 42.0 | 44.69 | 8.09 | -13.1 | -0.82 | 15.2 | 16.66 | 15.38 | 23.67 | 20.58 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.69 | -13.1 | 18.26 |
Quarterly ROCE Ratio Lantheus Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.54 | 38.98 | 41.45 | 32.62 | 48.7 | 53.44 | 65.9 | 36.45 | 49.88 | 47.24 | 35.92 | 36.0 | 33.13 | 16.82 | 0.41 | -5.18 | -6.2 | -4.35 | -0.16 | -0.71 | 6.72 | 15.17 | 28.93 | 34.23 | 57.44 | 73.22 | 82.97 | 66.96 | 122.01 | 153.85 | 208.26 | 183.1 | 171.28 | 104.4 | 14.25 | -41.73 | -48.96 | -44.38 | -33.96 | -16.27 | -20.12 | -16.74 | -18.02 | -8.02 | -8.02 | -4.17 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 208.26 | -48.96 | 35.09 |
ROCE Ratio of other stocks in the Diagnostics research industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
25.0 | $ 110.24 | -2.86 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
-89.9 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Waters Corporation
WAT
|
7.05 | $ 289.16 | -3.79 % | $ 17.2 B | USA |
 |
Exagen
XGN
|
-80.63 | $ 2.68 | -3.94 % | $ 57.8 M | USA |
 |
Enzo Biochem
ENZ
|
-22.04 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-8.59 | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
58.25 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-41.81 | $ 16.36 | -11.57 % | $ 176 M |  China |
 |
Sotera Health Company
SHC
|
70.91 | $ 13.13 | -3.03 % | $ 3.73 B | USA |
 |
Check-Cap Ltd.
CHEK
|
1809.55 | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
-4.81 | - | - | $ 1.31 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-2.26 | - | - | $ 562 M |  Britain |
 |
BioNano Genomics
BNGO
|
-75.05 | $ 1.16 | 0.87 % | $ 6.32 M | USA |
 |
DermTech
DMTK
|
-181.44 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-486.78 | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
33.2 | $ 62.25 | -5.81 % | $ 24.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
62.7 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
12.48 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-18.87 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-347.69 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-15.41 | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
-219.45 | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
1.9 | $ 23.53 | -4.74 % | $ 654 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
9.75 | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
0.8 | $ 159.16 | -3.62 % | $ 7.89 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
21.7 | $ 195.51 | -1.33 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
-120.24 | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
4.4 | - | -16.95 % | $ 1.54 M | USA |
 |
Biocept
BIOC
|
-360.98 | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
4.92 | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
-93.18 | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
-365.72 | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Motus GI Holdings
MOTS
|
-443.13 | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
1.9 | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
-51.22 | $ 8.7 | -4.92 % | $ 1.89 B | USA |
 |
Chembio Diagnostics
CEMI
|
-132.81 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
16.06 | $ 264.2 | -1.56 % | $ 22 B | USA |
 |
Psychemedics Corporation
PMD
|
-43.78 | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-52.81 | $ 25.97 | -4.52 % | $ 33.7 M | USA |
 |
CareDx, Inc
CDNA
|
-10.16 | $ 16.78 | -3.95 % | $ 894 M | USA |
 |
Quotient Limited
QTNT
|
232.42 | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Syneos Health
SYNH
|
11.41 | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
376.98 | - | 5.66 % | $ 22.7 M | Britain |
 |
VolitionRx Limited
VNRX
|
108.5 | $ 0.2 | 1.87 % | $ 19.2 M |  Singapore |
 |
Bioventus
BVS
|
29.32 | $ 8.94 | -3.46 % | $ 596 M | USA |
 |
Co-Diagnostics
CODX
|
-47.68 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Meridian Bioscience
VIVO
|
13.43 | - | - | $ 1.49 B | USA |
 |
Danaher Corporation
DHR
|
8.93 | $ 181.52 | -3.27 % | $ 129 B | USA |
 |
Surmodics
SRDX
|
-4.75 | - | - | $ 608 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-281.17 | $ 4.29 | -6.54 % | $ 2.3 M | USA |